INTRODUCTION
Predicting response to treatment has been the Holy Grail of surgical oncologists and gastroenterologists since the introduction of adjuvant therapy. The introduction of neoadjuvant therapy brought the goal a step closer, as pathological outcome could now be correlated with pretreatment markers. Neoadjuvant therapy has rapidly gained a role in the management of esophageal cancer, because the prognosis of esophageal cancer is so bad and the results of surgery, the mainstay of treatment, so poor. Surgical publications report that only about 25% of carefully selected patients undergoing surgery can hope to survive long-term. Since the surgical group represents, at most, 20-30% of all esophageal cancers in the community, the contribution of surgery to survival is less than 10%. And since many patients are unsuitable for curative surgery because of age or comorbid disease, other options are imperative. domized trial would require several hundred patients to prove statistically significant benefit but the evidence is accumulating that neoadjuvant systemic treatment is effective for esophageal cancer, as it is for other solid malignancies. Earlier randomized trials failed to confirm a survival advantage for neoadjuvant therapy, but these were compromised by trial design and inefficient treatment protocols. Most published trials on neoadjuvant therapy for esophageal cancer, which failed to show an advantage, are too small to prove or disprove a survival for any but the largest difference. Some trials have pooled adenocarcinoma and squamous carcinoma ignoring their differences in biological behavior. Some have employed single agent chemotherapy. 2 Others have given chemotherapy and radiotherapy consecutively rather than concurrently. 3 Larger trials have recently been published comparing preoperative systemic chemotherapy with surgery alone and these show a survival advantage favoring systemic therapy. The Rotterdam study found that median survival of 18.7 versus 11 months was significantly different in 160 patients treated with cisplatin and etoposide. 4 The Medical Research Council in the United Kingdom reported a survival difference of 17.6 versus 13.3 months to be significantly different when 802 patients were randomized to neoadjuvant cisplatin and 5-fluorouracil or surgery alone. 5 But neoadjuvant therapy is costly, time consuming and toxic. The ability to predict response and survival following response would be invaluable in patient management. For these reasons the need for outcome markers in the management of esophageal cancer are most pressing.
METHODS
A search was undertaken of the Medline database for references to predictive markers of response to neoadjuvant therapy, neoadjuvant therapy, esophagus, stomach and predicting response. The references of these publications were further scanned for appropriate references in the text and reference lists. Only references to response predictors in clinical context were included.
RESULTS

Tissue markers of response
The study of markers of response is in its infancy and the literature rudimentary. Most studies have correlated tissue concentration of molecular markers in the pretreatment biopsy with response to treatment in the resected specimen and/or outcome following treatment. Markers have usually been identified by immunocytochemical staining techniques.
For adenocarcinoma the best evidence for a predictive marker comes from the study of Duhaylongsod et al. 6 on c-erb B2 and p53 protein expression in the pretreatment biopsy specimen of 42 patients. Both c-erb B2 negativity and p53 positivity significantly correlated with the presence of residual disease in the resected specimen after treatment. P53 negativity predicted a favorable response to neoadjuvant chemotherapy (cisplatin and 5-FU) and irradiation and improved survival.
Sauter et al. 7 examined TGFa in 31 patients with localized adenocarcinoma receiving high dose chemoradiation and compared pretreatment expression with post-treatment values. While TGFa expression was not associated with survival, patients with persistent or increased expression had a worse prognosis.
For squamous cell carcinoma, there is a number of markers that have shown promise. Few have been compared with one another and correlation is inconsistent. Hickey et al. 8 in one of the earliest of such studies compared response with expression of the nuclear marker proliferating cell nuclear marker (PCNA) and epithelial cell growth factor (EGFR) and found that patients negative for both markers were more likely to have a complete response and to survive long-term, while patients positive for both were likely to respond poorly and to succumb to the disease.
Kitamura et al. 9 assayed p53 protein and Ki-67 antigen expression in biopsy specimens of 95 advanced esophageal cancers immunohistochemically. All patients received one course of either chemoradiotherapy or hyperthermo-chemoradiotherapy preoperatively. Forty-one per cent of specimens were positive for p53 protein staining and treatment was histopathologically effective in 72%, while the efficiency rate was 59% in p53 negative patients.
Shimada et al. 10 correlated p53 and cyclin D1 expression in pretreatment biopsy samples with sensitivity to cisplatin in 59 patients with esophageal squamous cell carcinoma receiving cisplatin chemotherapy followed by esophagectomy. They found that p53 expression in the pretreatment biopsy samples indicated resistance to cisplatin, but no correlation between cyclin D1 expression and histologic effect.
Sarbia et al. 11 also examined the prognostic impact of cyclin D1 expression, as detected by immunohistochemistry, and concluded that expression of cyclin D1 in carcinomas with multimodal treatment was correlated with poor response to chemotherapy but not with overall survival.
Moreira et al. 12 studied the predictive value of apoptosis immunohistochemically in 55 samples of esophageal squamous cell carcinoma using the BM1 Mab. Sections from patients not treated, or preoperatively treated by chemotherapy, radiation or both were compared. Their results suggested that in situ assessment of apoptotic response better correlates to the apoptosis induced by radiation than that by chemotherapy.
Sarbia et al. 13 assayed pretreatment tumor biopsies immunohistochemically for expression of p53, Bcl-2, Bax, and Bcl-X(L). No correlation was found between the expression of Bcl-2 and Bax and the response to chemotherapy. Patients treated by radiochemotherapy and surgery with p53-negative tumors had a significantly better outcome than patients with p53-positive tumors (mean survival, 31.1 months vs 11.3 months).
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While current markers may prove helpful, none may be relied on to predict response for the individual patient. Kim et al. 14 evaluated serial CEA levels in 90 patients with potentially resectable adenocarcinoma treated with preoperative chemotherapy. Serum CEA levels were assayed before treatment and serially thereafter. CEA positivity rate before chemotherapy was 22% and after chemotherapy it dropped to 19%. An increasing CEA level predicted relapse and correlated well with visceral involvement. Clinical responses correlated with declining levels of CEA.
Serum marker of response
McDonnell et al. 15 examined the serum profile of vascular endothelial growth factor (VEGF) in patients with both adenocarcinoma and squamous cell carcinoma, before, during and after treatment with chemoradiotherapy. Levels were elevated in cancer patients compared with controls. There was no reduction in levels during therapy. Levels fell following resection but rose rapidly to preoperative values. At three months, values had returned to normal. They concluded that VEGF levels could not be used as markers of response because of a source of VEGF other than tumor.
Quillien et al. 16 examined serum markers CYFRA 21-1, TPA and SCC in 96 patients with squamous cell carcinoma. Sensitivity was 42% for CYFRA 21-1, 40% for TPA and 37% for SCC. Pre-treatment levels of CYFRA 21-1 correlated with histologic response. CYFRA 21-1 was the only marker that distinguished significantly different survival curves, but not in multivariate analysis where treatment was the only independent factor. Nakamura et al. 17 assessed the clinical value of CYFRA 21-1 in comparison with SCC-Ag, CEA and CA19-9 in 112 patients with squamous cell carcinoma. The diagnostic sensitivity of CYFRA 21-1 was 34%, which was superior to SCC-Ag (28.6%), CEA (12.5%), and CA19-9 (6.3%). Levels of CYFRA 21-1 correlated closely with stage. CYFRA 21-1 levels also correlated with clinical response to chemotherapy or chemoradiotherapy.
These reports suggest that CYFRA 21-1 may be the most useful serum marker currently available. While reports of its diagnostic role are conflicting all suggest a role for monitoring therapeutic response.
DISCUSSION
Current approaches to predicting success of neoadjuvant therapy are crude and the results inconsistent. A range of factors accounts this for. Most rely on immunohistochemical techniques, which are sensitive to a range of confounding variables. The term response needs to be defined and in the context of upper GI cancer it must be complete or almost complete to translate to a significant survival advantage. A response marker that reliably identifies a cohort of patients with the potential for response can only be recognized when a treatment protocol is introduced that exploits this potential. There is a bias in the literature towards positive results that may overestimate positive correlation. Many negative studies, which may counterbalance the current literature, might never be published. We know that the majority of patients with esophageal cancer have systemic disease at presentation. For other solid malignancies, such as colon and breast, the contribution of systemic therapy is in the order of 5-10%. Very large cohorts are required to confirm as significant a difference of this size. The carcinogenic process is multifactorial and the absence of one molecular marker does not preclude other pathways in malignant transformation to a common end point.
In the future, advances in microarray technology hold promise of access to clean biological data, including prognostic indicators of response, which may make future treatment more predictable. For the moment, response and outcome prediction remain as attractive and as illusive as ever.
